Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a novel anti-hepatitis B virus agent via Sp1.
Hayakawa M, Umeyama H, Iwadate M, Taguchi YH, Yano Y, Honda T, Itami-Matsumoto S, Kozuka R, Enomoto M, Tamori A, Kawada N, Murakami Y. Hayakawa M, et al. Among authors: kozuka r. Sci Rep. 2020 Jan 8;10(1):47. doi: 10.1038/s41598-019-56842-9. Sci Rep. 2020. PMID: 31913341 Free PMC article.
Changes in sequences of core region, interferon sensitivity-determining region and interferon and ribavirin resistance-determining region of hepatitis C virus genotype 1 during interferon-alpha and ribavirin therapy, and efficacy of retreatment.
Kozuka R, Enomoto M, Hai H, Ogawa T, Nakaya M, Hagihara A, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Kawada N. Kozuka R, et al. Hepatol Res. 2012 Dec;42(12):1157-67. doi: 10.1111/j.1872-034X.2012.01046.x. Epub 2012 Jun 3. Hepatol Res. 2012. PMID: 22672644
Long-Term Outcome of Sequential Therapy with Lamivudine Followed by Interferon-β in Nucleoside-Naive, Hepatitis B e-Antigen-Positive Patients with Chronic Hepatitis B Virus Genotype C Infection.
Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Hayashi T, Kohmoto MT, Jomura H, Morikawa H, Murakami Y, Shiomi S, Kawada N. Enomoto M, et al. Among authors: kozuka r. J Interferon Cytokine Res. 2015 Aug;35(8):613-20. doi: 10.1089/jir.2014.0234. Epub 2015 Apr 17. J Interferon Cytokine Res. 2015. PMID: 25884105
Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b.
Tamori A, Yoshida K, Kurai O, Kioka K, Hai H, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Tamori A, et al. Among authors: kozuka r. Hepatol Res. 2016 Dec;46(13):1311-1320. doi: 10.1111/hepr.12689. Epub 2016 Apr 5. Hepatol Res. 2016. PMID: 26932745
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Yoshida K, Hai H, Tamori A, Teranishi Y, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Yoshida K, et al. Among authors: kozuka r. Int J Mol Sci. 2017 May 3;18(5):962. doi: 10.3390/ijms18050962. Int J Mol Sci. 2017. PMID: 28467359 Free PMC article.
The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Kozuka R, Hai H, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A. Kozuka R, et al. J Viral Hepat. 2018 May;25(5):535-542. doi: 10.1111/jvh.12850. Epub 2018 Jan 17. J Viral Hepat. 2018. PMID: 29274188 Clinical Trial.
44 results